Amgen Presents New Data on UPLIZNA and KRYSTEXXA at ACR Convergence 2024

Amgen (NASDAQ:AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheum...

November 15, 2024 | Friday | News
MSD Acquires Global License for LM-299, a Novel PD-1/VEGF Bispecific Antibody from LaNova Medicines

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology ...

November 15, 2024 | Friday | News
BioNTech Acquires Biotheus to Strengthen Oncology Pipeline with Bispecific Antibody Asset BNT327/PM8002

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) announced the signing of a definitive agreement for...

November 14, 2024 | Thursday | News
Gilead’s Lenacapavir Demonstrates Strong Efficacy and High Adherence in Phase 3 PURPOSE 2 Trial for HIV Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stu...

November 14, 2024 | Thursday | News
NurExone Gains EMA Orphan Designation for ExoPTEN, Advancing Spinal Cord Injury Therapy Across Europe

NurExone Biologic Inc.  a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the European Medici...

November 14, 2024 | Thursday | News
Exact Sciences to Present Key Findings on Multi-Cancer Early Detection Test at AACR Conference in San Diego

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant adv...

November 14, 2024 | Thursday | News
New Survey Reveals Critical Gaps in Care for Gynaecologic Cancer Patients, Highlighting Unmet Needs in Treatment Access and Support

GSK plc (LSE/NYSE: GSK) announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecolog...

November 13, 2024 | Wednesday | News
Alexion and Merck Report Positive Phase 3 KOMET Trial Results for KOSELUGO in Treating Adult Patients with Neurofibromatosis Type 1

Alexion, AstraZeneca Rare Disease and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the ...

November 13, 2024 | Wednesday | News
IDEAYA Secures Global Rights to Biocytogen’s Innovative BsADC Candidate, IDE034

IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...

November 12, 2024 | Tuesday | News
Zai Lab and argenx Secure Historic NMPA Approval for First CIDP Treatment in China

First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab&rs...

November 12, 2024 | Tuesday | News
Perceptive eClinical Launches ClinPhone 5: An Innovative RTSM Platform to Transform Clinical Trials

Perceptive eClinical, part of Perceptive Group, is pleased to announce the launch of ClinPhone 5, a ground-breaking new Randomization and Trial Supply Mana...

November 12, 2024 | Tuesday | News
ResQ Pharma Receives PDUFA Date for FDA Review of LipidRescue Kit for Life-Threatening Anesthetic Reactions

ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, announced that it has received a P...

November 12, 2024 | Tuesday | News
Alteogen and Daiichi Sankyo Partner to Develop Subcutaneous ENHERTU® Using Novel Hyaluronidase Technology

Alteogen Inc. (KOSDAQ:196170) announced that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms o...

November 11, 2024 | Monday | News
Gilead Sciences to Present Groundbreaking HIV Research at HIV Glasgow 2024, Highlighting Advances in Treatment and Prevention

Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...

November 08, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close